Shows
Neural Pharm PodcastMake America Healthy Again: the Podcast EditionReferences: Psychedelics legislation in Colorado Springs: https://gazette.com/health/fountain-joins-colorado-springs-in-seeking-to-regulate-fledgling-psychedelic-mushroom-industry/article_22a66456-a1da-11ef-a515-57588c741084.htmlOregon Psilocybin Ballot Measure Results: https://www.opb.org/article/2024/11/07/psilocybin-ban-mushroom-hallucinogenic-ballot-politics-elections-oregon/Vermont Psychedelic Working Group Final Report: chrome-extension://efaidnbmnnnibpcajpcglclefindmkaj/https://legislature.vermont.gov/assets/Legislative-Reports/The-Psychedelic-Therapy-Advisory-Working-Group_Final-Report.pdfUS Life Expectancy Expected to Decline to 66th Globally by 2050: https://www.healthdata.org/news-events/newsroom/news-releases/increases-us-life-expectancy-forecasted-stall-2050-poorer-health#:~:text=Life%20expectancy%20in%20the%20US,2022%20to%2066th%20in%202050United Healthcare uses faulty AI to deny claims: https://www.cbsnews.com/news/unitedhealth-lawsuit-ai-deny-claims-medicare-advantage-health-insurance-denials/
2025-01-0640 min
Neural Pharm PodcastKanna Alkaloids: Nature's MDMA?Show notes and references:* Please note: This was recorded prior to the election on Nov 5. We will discuss the results and predictions for the future of healthcare policy in America in our next edition.”Kanna references: Bennett, A. C., et al. "Sceletium tortuosum may delay chronic disease progression via alkaloid-dependent antioxidant or anti-inflammatory action." Journal of physiology and biochemistry 74.4 (2018): 539-547.Chiu, Simon, et al. "Proof-of-concept randomized controlled study of cognition effects of the proprietary extract Sceletium tortuosum (Zembrin) targeting phosphodiesterase-4 in cognitively healthy subjects: implications for Alzheimer’s dementia." Evidence-Based Complementary and...
2024-11-201h 00
Neural Pharm PodcastBreaking down the FDA Advisory Panel Decision on MDMA**Note this was recorded the first week of July before President Biden announced he would not run for re-election. I know that feels like a lifetime ago but just jump in your time machine for a bit at the beginning of the podcast please. We will likely start our next episode on the pharmacology of Kanna with a “catch up” on Kamala Harris v Trump**Footnotes, References and corrections:See below to watch the live stream of the FDA advisory panel decision on MDMA Assisted Therapy; a review of the MAPP1 and MAPP2 trial data:
2024-08-091h 01
Neural Pharm PodcastGuest Interview with Shuna Morelli, author of "49 Days" and founder of Body Mind Bridge InstituteFor more information on Shuna’s work visit: https://www.shunamorelli.com/ Get full access to Neural Pharm at neuralpharm.substack.com/subscribe
2024-04-1834 min
Neural Pharm PodcastGuest Interview with Danielle Daniel, Founder of Microdosing Humboldt**To learn more about Danielle and the services she provides, go to the Microdosing Humboldt website: https://www.microdosinghumboldt.com/home or follow her on Instagram at: https://www.instagram.com/microdosinghumboldt/ ** Get full access to Neural Pharm at neuralpharm.substack.com/subscribe
2024-03-2145 min
Neural Pharm PodcastMescaline: Primer on history and pharmacologyThanks for reading Neural Pharm! Subscribe for free to receive new posts and support my work.References:Cassels B, et al. Dark classics in chemical neuroscience: mescaline. ACS Publications. 9 Sept 2018. https://pubs.acs.org/doi/10.1021/acschemneuro.8b00215Dinis-Oliveira RJ, et al. Pharmacokinetic and pharmacodynamic aspects of peyote and mescaline: clinical and forensic repercussions. 1 Aug 2019. Current Molecular Pharmacology.https://www.ingentaconnect.com/contentone/ben/cmp/2019/00000012/00000003/art00003Engel L, et al. Mescaline, peyote, and San Pedro: is sustainability important for cacti consumers? 18 Aug 2023. Journal of Psychedelic Studies. https://akjournals.com/view...
2024-03-1138 min
Neural Pharm PodcastGuest Interview with Ben Malcolm, PharmD, MPHThanks for reading Neural Pharm! Subscribe for free to receive new posts and support my work.Footnotes:—Yes I will acknowledge that I mispronounced “anecdotal” a few times during this interview. For some reason this is always one of those tricky words for me to say, and even past Presidents and Presidential candidates have mispronounced words from time to time. If you want to roast me for it (politely) feel free to leave a comment.—For reference to the article that Ben Malcolm mentioned in the interview about Ketamine being non-inferior to Elect...
2024-02-2641 min
Neural Pharm PodcastGLP 1 Agonists: Therapies for type II diabetes, obesity, and addiction(?)Thanks for reading Neural Pharm! Subscribe for free to receive new posts and support my work.References:Arrone L, et al. Continued Treatment with Tirzepatide for Maintenance of Weight Reduction in Adults with Obesity: the SURMOUNT-4 Randomized Clinical Trial. JAMA. 11 Dec 2023. https://jamanetwork.com/journals/jama/fullarticle/2812936Attia P and Gifford B. Outlive: The Science & Art of Longevity First edition., Harmony, 2023. Bliss M. The History of a Wonderful Thing We Call Insulin. American Diabetes Association. 1 July 2019. https://diabetes.org/blog/history-wonderful-thing-we-call-insulinHendershot C. Use of...
2024-02-0743 min
Neural Pharm PodcastIbogaine Assisted TherapyIbogaine References:Alper K, et al. Ibogaine: Scientific Literature Overview. International Center for Ethnobotanical Education. 2012. Available at: chrome-extension://efaidnbmnnnibpcajpcglclefindmkaj/https://www.iceers.org/Documents_ICEERS_site/Scientific_Papers/ibogaine/ICEERS2012_Ibogaine_literature_compilation.pdfCorkery JM. Ibogaine as a Treatment for Substance Misuse: Potential Benefits and Practical Dangers. Progress in Brain Research. 2018(242); 217-257. https://www.sciencedirect.com/science/article/abs/pii/S0079612318300979?via%3DihubDalton C. A Detox Drug Promises Miracles if it Doesn’t Kill You First. Wired. 15 Sept 2019. https://www.wired.com/story/a-detox-drug-promises-miraclesif-it-doesnt-kill-you-first/Davis AK, et al. Subjective Ef...
2024-01-0644 min
Neural Pharm PodcastIntroduction to Kratom alkaloidsFootnotes:For more on how to help our nation’s veterans:https://www.va.gov/REACH/ Veteran crisis line: Dial 988 and press 1. Or text 838255. Seasonal Affectiveness Disorder. National Institute of Mental Health. https://www.nimh.nih.gov/health/publications/seasonal-affective-disorderKentucky Ibogaine Initiative: https://www.kentuckyibogaineinitiative.com/Huberman, Andrew. Mental Health Toolkit: Tools to bolster your mood and mental health. Huberman Lab [podcast]. 30 Oct 2023References on Kratom: FDA and Kratom. https://www.fda.gov/news-events/public-health-focus/fda-and-kratom. 21 July 2023. Gandhi D, et al...
2023-11-1740 min
Neural Pharm PodcastGuest Interview: Austin Rogers and Cheri Thomas of Northwest Ketamine Clinic*For listeners in the Seattle/Tacoma/Bellevue area: Mention this podcast and receive 10% off an initial ketamine treatment series at NW Ketamine Clinic For more information go to: https://nwketamineclinics.com/ Get full access to Neural Pharm at neuralpharm.substack.com/subscribe
2023-11-0342 min
Neural Pharm PodcastIt's a Mad Honey WorldFoot notes: UK article on Psilocybin therapy cost effectiveness:McCrone P, et al. Cost effectiveness of psilocybin assisted therapy for severe depression: exploratory findings from a decision analytic model. Psychological Medicine. 2 June 2023. https://www.cambridge.org/core/journals/psychological-medicine/article/costeffectiveness-of-psilocybinassisted-therapy-for-severe-depression-exploratory-findings-from-a-decision-analytic-model/8594CAC2F8D60F8C7B9A1CE3C3195B74MDMA Assisted Therapy for Social Anxiety Disorder—Phase II trial being conducted at Portland (OR) Psychotherapy, link here for those interested in finding out more information or enrolling: https://portlandmdmatherapy.com/participate/Krane, K. HHS Call to reschedule ma...
2023-10-2428 min
Neural Pharm PodcastGuest Interview with Jeff Stevens, CEO of Psyched WellnessFootnotes:To find out more on Psyched Wellness, or to order Calm to have it shipped to home, click on the link here: For more on Amanita Muscaria, please view the article I published on my Substack by clicking the link here Wired article on microdosing: https://www.wired.co.uk/article/microdosing-workplace-shroom-boom#intcid=_wired-uk-bottom-recirc_397cdbf7-d656-4f04-b4a2-111a2dd3ef9f_entity-topic-similarity-Microdosing Amanita for neuropathic pain: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4614567/*Be on the lookout for an...
2023-10-1940 min
Neural Pharm PodcastAyahuasaca, DMT, and 5-MeODMT***Please take a couple minutes to complete a brief survey about the podcast here. If you have any specific open ended feedback for the podcast, please feel free to leave a comment below or email at cburns@neuralpharm.net*** References: “Ayahuasca and 5 Me-ODMT.” UC Berkeley Center for the Science of Psychedelics. Last accessed 28 Sept 2023. https://psychedelics.berkeley.edu/substance/ayahuasca/Bernal A, et al. Reactivations after 5-methoxy-N,N-dimethyltryptamine use in naturalistic settings: an initial exploratory analysis of the phenomenon’s predictors and its emotional valence. Frontiers in Psychiatry. 2022; 13: 1049643Halberstadt A. Di...
2023-09-2934 min
Neural Pharm PodcastKetamine: Anesthetic and rapid anti-depressantReferences:Article referenced in the beginning:Martinez-Marmol, et al. Hericerin derivatives activates a pan neurotrophic pathway in central hippocampal neurons converging to ERK1/2 signaling enhancing spacial memory. Journal of Neurochemistry. 2023(165);6: 791-808Ballard E and Zarate C. The role of disassociation in ketamine’s anti-depressant effects. Nature Communications. 2020: 6431Bobo WV, et al. Ketamine for treatment resistant unipolar and bipolar major depression: Critical review and implications for clinical practice. Depression and Anxiety. 6 April 2016.Esketamine [package insert]. Janssen Neuroscience. July 2023. Fava M, et al. Double blind, placebo controlled do...
2023-09-1736 min
Neural Pharm PodcastPsychedelic Microdosing and Drug InteractionsReferences: Cheung T. COMPASS Announces Positive Outcome of 25 mg COMP360 Psilocybin Therapy as Adjunct to SSRI Anti-depressant in Open-Label, Treatment-Resistant Depression Study. COMPASS Health. 13 Dec 2021 [press release]. Grinspoon P. The Popularity of Microdosing of Psychedelics: What Does the Science Say? Harvard Health. 19 Sept 2022. Gukasyan N, et al. Attenuation of Psilocybin Mushroom Effects During and After SSRI/SNRI Anti-depressant Use. Sage Journals. 2023 Jul; 37(7): 707-716Malcolm B and Thomas K. Serotonin Toxicity of Serotonergic Psychedelics. Psychopharmacology. 2022;239: 1881-1891Perez E, et al. The Psilocybin-Blunting Effects of SSRIs and Anti-depressants. Psychedelic...
2023-09-0536 min
Neural Pharm PodcastGuest Interview with Aaron Orsini: author, researcher, and founder of Autistic Psychedelic CommunityDr. Christopher Toney, PharmD Dr. Colby Burns, PharmD Aaron Orsini is an autistic psychedelic educator, author and researcher. He has published four books about his area of focus — Autism On Acid (2019), Autistic Psychedelic (2021), Introduction to Psychedelic Autism (2022), and Psychedelic Autism (2023) — and presently serves as a psychedelic autism research co-author collaborator to University College London and an advisor to an ADAPT drug education study funded by Organization for Autism Research. Aaron is also a lecturer on psilocybin facilitation for Alma Institute and SoundMind Institute in Oregon, Naropa University in Colorado, and the lead instructor for his first-of-kind facilitation-focused inte...
2023-08-2352 min
Neural Pharm PodcastPsilocybin for Pain and TBIReferences:Structural comparison of DMT, psilocin, and serotonin. Adkins A and Ferguson MC. “Research update: MDMA and psilocybin for pain management.” Practical Pain Management. 18 June 2022. https://www.practicalpainmanagement.com/news/research-update-mdma-and-psilocybin-for-pain-management. Accessed 30 July 2023Bornemann J, et al. “Self-medication for chronic pain using class psychedelics: A qualitative investigation to inform future research.” Frontiers in Psychiatry. 18 June 2022. https://www.practicalpainmanagement.com/news/research-update-mdma-and-psilocybin-for-pain-management Accessed 31 July 2023. Fanciullacci M, et al. “Brief report: phantom limb pain: sub-hallucinogenic treatment with lysergic acid diethylamide (LSD).” Headache. 1977 July; 17(3): 118-119. https://pubmed.ncbi.nlm.nih.gov/893080/ Accessed 30 July 2023Flanagan T...
2023-08-0231 min
Neural Pharm PodcastGuest Interview with George Sellhorn of Flourish Labs (OR)George Sellhorn Ph.D, is the founder, owner and Principal Scientist of Flourish Labs in Portland Oregon and earned his Ph.D. in Molecular Plant Sciences from Washington State University (2006) and his B.S. in Biology from Indiana University (1999). George has worked in both academia and the biotechnology industries from 2006-2021 working on projects such as HIV vaccine development, production, characterization and pre-clinical evaluation as well as bioconjugate-based therapeutics including pegylated interferon for multiple sclerosis, bifunctional antibodies and antibody drug conjugates for breast cancer and poly(carboxybetaine) L-asparaginase bioconjugates for acute lymphoblastic leukemia.George has 23 years of...
2023-07-2652 min
Neural Pharm PodcastPsilocybin for mental healthNotes: Per Christopher Toney, a reminder that psilocybin dosing is based on dry weight of the whole mushrooms, for those curious about how dosing is calculated. How well does this approximate actual psilocybin content? This will be a good future topic for discussion. References:Link to FDA’s Considerations for Clinical Investigations of Psychedelic Drugs (Accessed 11 July 2023): https://www.fda.gov/regulatory-information/search-fda-guidance-documents/psychedelic-drugs-considerations-clinical-investigations. Bogenschutz MP, et al. Percentage of heavy drinking days following psilocybin assisted psychotherapy vs placebo in the treatment of patients with alcohol use disorder: a randomized clinical tr...
2023-07-1738 min
Neural Pharm PodcastReview of MDMA and LSD, intro to psilocybinReferences:Gotvaldova K, et al. "Extensive Collection of Psychotropic Mushrooms with Determination of Their Tryptamine Alkaloids". International Journal of Molecular Sciences. 2023 (22): 14068.Halpern J, Roth BL "Hallucinogens and dissociative agents naturally growing in the United States". Pharmacology & Therapeutics. 2004; 102 (2): 131–8.Huberman A. The science of MDMA and its therapeutic uses: benefits and risks. Huberman Labs (podcast). 12 Jun 2023Pollan M. How to change your mind: the new science of psychedelics. Penguin Press. 2019Sumner R, et al. Microdosed LSD: Dose day outcomes from a home-administered randomized controlled trial. 2023. Unpublished (information from poster pr...
2023-07-0526 min
Neural Pharm PodcastLSD: Part II, The Modern Era***Disclaimer: this podcast is intended for informational purposes only on the safety and efficacy data of the substances discussed. As healthcare professionals, we do not advocate for or against the use of substances which are considered illicit by the United States Drug Enforcement Administration***References: Bonson KR, et al. Chronic administration of serotonergic anti-depressants attenuates the subjective effects of LSD in humans. Neuropsychopharmacology. 1996; 14(6)Gasser P, et al. Safety and efficacy of lysergic acid diethylamide-assisted psychotherapy for anxiety associated with life-threatening diseases. The Journal of Nervous and Mental Disease. 2014; 202(7): 513-520Lopez-Gimenez JF...
2023-06-2228 min
Neural Pharm PodcastLSD Part 1: History and Early Clinical researchAudio Correction: Colby misspoke 4:15: meant to say “Methergine is used for postpartum hemorrhage after delivery,” said “hemorrhage after bleeding” (which of course is redundant and a mistake). Article on Ergotamine association with the Salem Witch Trials (from the Outside Hustle, Colby’s other blog): Blotter Art examples: https://keseyblotterart.com/References: Bryant C, Clark J. “How LSD Works.” Stuff You Should Know [podcast] 5 May 2016. Dyck E. LSD: a new treatment emerging from the past. CMAJ. 2015 Aug 4;187(14):1079–80. doi: 10.1503/cmaj.141358. Epub ahead of print. PMID: 26243813; PMCID: PMC4592308.Dyck, E. (2006...
2023-06-1434 min
Neural Pharm PodcastEpisode 1: Introduction/MDMA Therapy for PTSDIntroducing the Neural Pharm Podcast, featuring your hosts Colby Burns, PharmD, and Christopher Toney, PharmD. Episode 1 establishes the mission of the podcast, and covers the groundbreaking MAPP1 and MAPP2 trials that established MDMA as a breakthrough therapy for PTSD. We also cover key safety data including drug interactions, pharmacokinetics (or metabolism), and pharmacogenomics (or gene-drug interactions). Come join us! ***Correction Alert: The Ted talk referenced by Colby in the conclusion of the podcast was given by Dr. Ben Sessa, not Sassa (see the attached video in the reference section)****References: * Mitchell...
2023-06-0723 min
Pharmacy Podcast NetworkIntroduction/MDMA Therapy for PTSD | Neural PharmIntroducing the Neural Pharm Podcast, featuring your hosts Colby Burns, PharmD, and Christopher Toney, PharmD. Episode 1 establishes the mission of the podcast, and covers the groundbreaking MAPP1 and MAPP2 trials that established MDMA as a breakthrough therapy for PTSD. We also cover key safety data including drug interactions, pharmacokinetics (or metabolism), and pharmacogenomics (or gene-drug interactions). Come join us!
***Correction Alert: The Ted talk referenced by Colby in the conclusion of the podcast was given by Dr. Ben Sessa, not Sassa (see the attached video in the reference section)****
References:
Mitchell J...
2023-06-0623 min